Drugs / Lorazepam
Lorazepam
also known as
Ativan · LZP · Abbloraz · Intravenous route of active treatment · Loraz · Lorazepam civ · Lorazepam intensol · Lorazepam Mylan · +5 more
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansion | US (FDA) | ATIVAN | — | 1997-09-05 | fda.gov ↗ |
| Approved | US (FDA) | ATIVAN | — | 1977-09-30 | fda.gov ↗ |
Trials 67 · started per year
today
US approved 1977
1
2
2
1
4
2
3
4
3
3
5
1
3
5
5
3
2
3
2
2
1
1
3
4
1
1
19771978197919801981198219831984198519861987198819891990199119921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023202420252026202720282029
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 03 trials | ||||||
| Phase 0 | NCT07560878 | Mar 2026 → Dec 2030 expected | major depressive disorder | Mclean Hospital | Recruiting | No outcome recorded |
| Phase 0 | NCT04671836 | Jan → Dec 2022 | — | Northwell Health | Withdrawn | No outcome recorded |
| Phase 0 | NCT04923659 | May 2021 → Jul 2022 overdue | — | University Health Network, Toronto | Active not recruiting | No outcome recorded |
| Phase 114 trials | ||||||
| Phase 1 | NCT03053869 | Apr 2017 → Sep 2018 | delirium | McMaster University | Completed | No outcome recorded |
| Phase 1 | NCT01994668 | Jan → Feb 2014 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT01951144 | Oct 2013 → Jul 2014 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT02462109 | Mar 2013 | catatonia | Makerere University | Completed | No outcome recorded |
| Phase 1 | NCT01780519 | Jan 2013 → Sep 2016 | Alzheimer disease | Mayo Clinic | Completed | No outcome recorded |
| Phase 1 | NCT01275144 | Dec 2010 → Feb 2011 | major depressive disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01110616 | Jun → Oct 2010 | dementia | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT00826553 | Jan 2009 → Dec 2013 | delirium, respiratory failure | Vanderbilt University Medical Center | Terminated | No outcome recorded |
| Phase 1 | NCT00720421 | Jun → Aug 2008 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00513565 | Sep 2007 → May 2009 | mixed anxiety and depressive disorder | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00424697 | Mar → Dec 2007 | — | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00114569 | Mar 2005 → Apr 2007 | — | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Completed | No outcome recorded |
| Phase 1 | NCT00649818 | Dec 2004 | — | Mylan Pharmaceuticals Inc | Completed | No outcome recorded |
| Phase 1 | NCT00055549 | Mar 2003 → Nov 2009 | voice disorders | National Institute of Neurological Disorders and Stroke (NINDS) | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00123578 | Aug 2004 → Aug 2008 | substance-related disorder | University of California, Los Angeles | Withdrawn | No outcome recorded |
| Phase 210 trials | ||||||
| Phase 2 | NCT06496854 | Oct 2025 → Jan 2026 | — | University of Wisconsin, Madison | Withdrawn | No outcome recorded |
| Phase 2 | NCT05662228 | Jun 2023 → May 2026 | Down syndrome | University of Colorado, Denver | Completed | No outcome recorded |
| Phase 2 | NCT04646135 | Dec 2020 → Jul 2021 | — | Bambino Gesù Hospital and Research Institute | Unknown | No outcome recorded |
| Phase 2 | NCT03756038 | Jan → Mar 2019 | — | Maria Pacella | Terminated | No outcome recorded |
| Phase 2 | NCT02671760 | Feb → Jun 2016 | insomnia | Sequential Medicine Ltd | Completed | No outcome recorded |
| Phase 2 | NCT01949662 | Jan 2014 → Aug 2016 overdue | high grade malignant neoplasm | M.D. Anderson Cancer Center | Active not recruiting | No outcome recorded |
| Phase 2 | NCT01790490 | Feb 2011 → Mar 2012 | cocaine dependence | New York State Psychiatric Institute | Completed | No outcome recorded |
| Phase 2 | NCT00429702 | Oct 2007 → Aug 2009 | childhood malignant neoplasm | University of South Florida | Terminated | No outcome recorded |
| Phase 2 | NCT00229125 | Jul 2001 → Sep 2005 | alcohol withdrawal | National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Completed | No outcome recorded |
| Phase 2 | NCT00011297 | ? → Dec 2005 | alcohol dependence | National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Completed | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT03743649 | Jul 2019 → Dec 2028 expected | delirium, high grade malignant neoplasm, metastatic malignant neoplasm | M.D. Anderson Cancer Center | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT00465244 | Jan 2008 → May 2010 | epilepsy | Massachusetts General Hospital | Withdrawn | No outcome recorded |
| Phase 311 trials | ||||||
| Phase 3 | NCT07017452 | Aug → Dec 2025 overdue | benign prostatic hyperplasia | University of Manitoba | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT03338764 | May → Dec 2023 | insomnia | Sequential Medicine Ltd | Withdrawn | No outcome recorded |
| Phase 3 | NCT03331042 | Oct 2017 → Mar 2018 | insomnia | Sequential Medicine Ltd | Completed | No outcome recorded |
| Phase 3 | NCT02305797 | Jan 2015 → May 2016 | generalized anxiety disorder | Edgemont Pharmaceuticals, LLC | Completed | No outcome recorded |
| Phase 3 | NCT02374567 | Jan 2015 → Jun 2017 | anxiety disorder, dementia, depressive disorder, schizophrenia +1 | Hannover Medical School | Terminated | No outcome recorded |
| Phase 3 | NCT02239380 | Nov 2014 → Aug 2016 | — | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT02134366 | Jul 2014 → Jul 2017 | epilepsy syndrome | The Cooper Health System | Terminated | No outcome recorded |
| Phase 3 | NCT01901003 | Nov 2012 → Jun 2014 | — | Assistance Publique Hopitaux De Marseille | Completed | No outcome recorded |
| Phase 3 | NCT00343096 | Jun 2006 → Mar 2009 | epilepsy | Kamuzu University of Health Sciences | Terminated | No outcome recorded |
| Phase 3 | NCT00116064 | Jul 2004 → Jun 2005 | epilepsy | Kamuzu University of Health Sciences | Completed | No outcome recorded |
| Phase 3 | NCT00004297 | Nov 1995 → Feb 1999 | — | National Institute of Neurological Disorders and Stroke (NINDS) | Completed | No outcome recorded |
| Phase 413 trials | ||||||
| Phase 4 | NCT07428681 | Mar 2027 → Feb 2028 expected | delirium | University Hospital, Basel, Switzerland | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06852469 | Jul 2025 → Jun 2029 expected | post-traumatic stress disorder | VA Office of Research and Development | Recruiting | No outcome recorded |
| Phase 4 | NCT06004115 | Nov 2023 → Dec 2027 expected | anxiety, mixed anxiety and depressive disorder | Laureate Institute for Brain Research, Inc. | Recruiting | No outcome recorded |
| Phase 4 | NCT04004416 | Jan 2020 → Feb 2025 | bipolar disorder, major depressive disorder, schizoaffective disorder, schizophrenia +1 | University of Michigan | Completed | No outcome recorded |
| Phase 4 | NCT03090620 | Mar 2017 → Jul 2020 | poisoning | University of Colorado, Denver | Completed | No outcome recorded |
| Phase 4 | NCT01889602 | Jul 2013 → Aug 2016 | cognitive disorder | University of Minnesota | Completed | No outcome recorded |
| Phase 4 | NCT01877642 | Jun → Jul 2013 | — | Alexza Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 4 | NCT01121055 | Mar → Aug 2010 | — | Seoul National University Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT00721526 | Aug 2009 → Aug 2012 | alcohol dependence, anxiety disorder | University of New Mexico | Completed | No outcome recorded |
| Phase 4 | NCT00158873 | Sep 2004 → ? | — | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 4 | NCT00159133 | Nov 2001 → Jun 2006 | schizophrenia | Heinrich-Heine University, Duesseldorf | Completed | No outcome recorded |
| Phase 4 | NCT00044642 | Dec 2000 → Jul 2007 | generalized anxiety disorder | Nathan Kline Institute for Psychiatric Research | Completed | No outcome recorded |
| Phase 4 | NCT00000441 | ? → Dec 2000 | alcohol dependence | National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Completed | No outcome recorded |
| Phase not applicable13 trials | ||||||
| — | NCT06549426 | Apr 2025 → Dec 2029 expected | epilepsy | University of Twente | Recruiting | No outcome recorded |
| — | NCT02928328 | Oct 2016 → Dec 2018 | — | Aalborg University | Unknown | No outcome recorded |
| — | NCT02863614 | May 2015 → May 2017 | infertility disorder | University of Sao Paulo | Completed | No outcome recorded |
| — | NCT02056236 | Apr 2014 → Apr 2021 | cardiac arrest | University of Twente | Completed | No outcome recorded |
| — | NCT01556932 | Mar 2012 → May 2013 | — | Virginia Commonwealth University | Completed | No outcome recorded |
| — | NCT01843868 | Jan 2012 → Jun 2015 | non-Hodgkin lymphoma | Australasian Leukaemia and Lymphoma Group | Withdrawn | No outcome recorded |
| — | NCT01204255 | Nov 2010 → Apr 2011 | — | Virginia Commonwealth University | Completed | No outcome recorded |
| — | NCT01272778 | Oct 2010 → Apr 2011 | — | Orasi Medical, Inc. | Unknown | No outcome recorded |
| — | NCT00972985 | Sep → Dec 2009 | — | Orasi Medical, Inc. | Completed | No outcome recorded |
| — | NCT01566539 | Apr 2008 → Nov 2016 | — | Emory University | Completed | No outcome recorded |
| — | NCT00696033 | Jul 2007 → Dec 2008 | — | University Hospital, Strasbourg, France | Completed | No outcome recorded |
| — | NCT00846950 | Dec 2006 → May 2007 | — | Maastricht University Medical Center | Completed | No outcome recorded |
| — | NCT00337792 | Jun 2006 → Jul 2007 | — | Planned Parenthood League of Massachusetts | Terminated | No outcome recorded |
Also used as a comparator or background therapy in 65 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT00881556 Background | Aug 2009 → Sep 2015 | epidermolysis bullosa | Columbia University | Terminated | No outcome recorded |
| Phase 18 trials | ||||||
| Phase 1 | NCT05964647 Comparator | Feb 2024 → Jun 2025 | — | University Hospital, Basel, Switzerland | Completed | No outcome recorded |
| Phase 1 | NCT03300947 Comparator | Jan 2019 → Oct 2023 | obsessive-compulsive disorder | University of Arizona | Completed | No outcome recorded |
| Phase 1 | NCT03829839 Comparator | Mar 2016 → Aug 2017 | — | University Hospital, Bonn | Completed | No outcome recorded |
| Phase 1 | NCT02033707 Background | Apr 2014 → Feb 2019 | — | Johns Hopkins University | Completed | No outcome recorded |
| Phase 1 | NCT00902772 Comparator | May → Sep 2009 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00750802 Comparator | Sep → Dec 2008 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00736931 Comparator | Jul → Oct 2008 | epilepsy | UCB Pharma | Completed | No outcome recorded |
| Phase 1 | NCT00364429 Background | Jul 2005 | schizophrenia | GlaxoSmithKline | Terminated | No outcome recorded |
| Phase 29 trials | ||||||
| Phase 2 | NCT06859424 Background | Jul 2025 → Jun 2028 expected | B-cell chronic lymphocytic leukemia, acute myeloid leukemia, chronic myeloid leukemia, chronic myelomonocytic leukemia +3 | Center for International Blood and Marrow Transplant Research | Recruiting | No outcome recorded |
| Phase 2 | NCT04715230 Comparator | Jun 2021 → Oct 2022 | methamphetamine-induced psychosis | InterveXion Therapeutics, LLC | Terminated | No outcome recorded |
| Phase 2 | NCT04396327 Background | May → Jun 2020 overdue | insomnia | Sequential Medicine Ltd | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT03180632 Comparator | Jun 2017 → Jun 2018 | anxiety | St. Justine's Hospital | Completed | No outcome recorded |
| Phase 2 | NCT03021018 Comparator | Feb 2017 → Apr 2018 | epilepsy | UCB Biopharma S.P.R.L. | Completed | No outcome recorded |
| Phase 2 | NCT02564029 Comparator | Dec 2015 → Jan 2017 | photosensitive epilepsy | Pfizer | Completed | No outcome recorded |
| Phase 2 | NCT00807937 Comparator | Dec 2008 → May 2009 | generalized anxiety disorder | AstraZeneca | Completed | No outcome recorded |
| Phase 2 | NCT00431184 Comparator | Jan 2007 → Mar 2011 | manic bipolar affective disorder, schizoaffective disorder | Mclean Hospital | Completed | No outcome recorded |
| Phase 2 | NCT00095251 Comparator | Aug 2004 → Aug 2007 | delirium | Vanderbilt University | Completed | No outcome recorded |
| Phase 2/33 trials | ||||||
| Phase 2/3 | NCT06752616 Comparator | Dec 2024 → Dec 2027 expected | — | Lone Baandrup | Recruiting | No outcome recorded |
| Phase 2/3 | NCT00621478 Comparator | Feb 2008 → May 2012 | — | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Completed | No outcome recorded |
| Phase 2/3 | NCT00109395 Comparator | Sep 2004 → Sep 2007 | — | The Emmes Company, LLC | Completed | No outcome recorded |
| Phase 38 trials | ||||||
| Phase 3 | NCT06370442 Comparator | Jun 2024 → May 2025 | mental disorder | State University of New York - Upstate Medical University | Unknown | No outcome recorded |
| Phase 3 | NCT02147548 Comparator | Dec 2013 → Oct 2015 | — | Biocodex | Completed | No outcome recorded |
| Phase 3 | NCT01870024 Comparator | Jun 2013 → Feb 2018 | epilepsy | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 3 | NCT01827293 Comparator | Apr → Jun 2013 | peripheral vertigo | Shahid Beheshti University of Medical Sciences | Completed | No outcome recorded |
| Phase 3 | NCT01067144 Comparator | May 2010 → Jul 2016 | breast cancer, lung cancer | Stanford University | Terminated | No outcome recorded |
| Phase 3 | NCT00809146 Comparator | Jun 2009 → Jan 2011 | — | Robert Silbergleit | Completed | No outcome recorded |
| Phase 3 | NCT00735527 Comparator | May 2008 → Apr 2009 | epilepsy | All India Institute of Medical Sciences | Completed | No outcome recorded |
| Phase 3 | NCT00797277 Comparator | Jul 2006 → Jun 2009 | schizoaffective disorder, schizophrenia | National Taiwan University Hospital | Completed | No outcome recorded |
| Phase 424 trials | ||||||
| Phase 4 | NCT07552246 Background | Apr 2026 → Mar 2027 expected | mixed anxiety and depressive disorder | Duke Kunshan University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06799494 Background | Aug 2025 → Sep 2028 expected | human papilloma virus infection | Emory University | Recruiting | No outcome recorded |
| Phase 4 | NCT06429657 Background | Sep 2024 → Jan 2027 | intracerebral hemorrhage, intracranial hypertension, traumatic brain injury | Henry M. Jackson Foundation for the Advancement of Military Medicine | Suspended | No outcome recorded |
| Phase 4 | NCT05599126 Comparator | Jul 2024 → Dec 2025 | depressive disorder | Zhenghui YI | Unknown | No outcome recorded |
| Phase 4 | NCT06093451 Comparator | Jul 2023 → Jul 2024 | bipolar disorder, schizoaffective disorder, schizophrenia | Temple University | Unknown | No outcome recorded |
| Phase 4 | NCT04240626 Background | Jan 2021 → Jun 2026 overdue | morbid obesity | University of California, Davis | Active not recruiting | No outcome recorded |
| Phase 4 | NCT04156464 Comparator | Jul 2020 → Dec 2021 | alcohol withdrawal delirium | OSF Healthcare System | Unknown | No outcome recorded |
| Phase 4 | NCT03788889 Comparator | Apr 2019 | alcohol withdrawal | Santa Barbara Cottage Hospital | Withdrawn | No outcome recorded |
| Phase 4 | NCT03110900 Comparator | Sep 2017 → Apr 2018 | — | University of Arkansas | Terminated | No outcome recorded |
| Phase 4 | NCT03235531 Background | Jul 2017 → Jul 2019 | alcohol abuse, alcohol dependence, alcohol withdrawal | CAMC Health System | Unknown | No outcome recorded |
| Phase 4 | NCT03202550 Comparator | Jun 2017 → May 2019 | — | Johns Hopkins University | Completed | No outcome recorded |
| Phase 4 | NCT03012815 Comparator | Feb 2017 → Mar 2021 | alcohol withdrawal | Mayo Clinic | Completed | No outcome recorded |
| Phase 4 | NCT02407704 Background | Mar 2015 → Nov 2016 | major depressive disorder | Kirk Erickson, PhD | Completed | No outcome recorded |
| Phase 4 | NCT02078336 Comparator | Dec 2013 → Jul 2025 overdue | — | Universitaire Ziekenhuizen KU Leuven | Active not recruiting | No outcome recorded |
| Phase 4 | NCT02367755 Comparator | Aug 2013 → Dec 2016 | cardiac arrest | Far Eastern Memorial Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT01330459 Comparator | Feb → Oct 2011 | — | Elizabeth Micks | Completed | No outcome recorded |
| Phase 4 | NCT01441843 Comparator | Oct 2010 → Sep 2011 | anxiety | Erasmus Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT01050478 Background | Mar 2010 → Dec 2011 | — | Janssen Cilag N.V./S.A. | Completed | No outcome recorded |
| Phase 4 | NCT01305707 Comparator | Jul 2009 → Jul 2014 | major depressive disorder | Hospital Universitari de Bellvitge | Terminated | No outcome recorded |
| Phase 4 | NCT00624780 Comparator | May 2009 → Apr 2012 | generalized anxiety disorder | Viatris Inc. | Completed | No outcome recorded |
| Phase 4 | NCT00786318 Comparator | Sep 2008 → Jul 2011 | delirium, psychotic disorder | George Washington University | Withdrawn | No outcome recorded |
| Phase 4 | NCT01011634 Comparator | May 2007 → Nov 2008 | pregnancy disorder with abortive outcome | University of California, San Francisco | Terminated | No outcome recorded |
| Phase 4 | NCT00457366 Comparator | May 2006 → Aug 2008 | — | University of Southern California | Completed | No outcome recorded |
| Phase 4 | NCT00249366 Comparator | Apr 2001 → May 2003 | alcohol withdrawal | Virginia Commonwealth University | Completed | No outcome recorded |
| Phase not applicable12 trials | ||||||
| — | NCT06467474 Background | Mar 2024 → Jun 2025 overdue | major depressive disorder | Ricardo Alberto Moreno, M.D., Ph.D. | Recruiting | No outcome recorded |
| — | NCT02362256 Background | May → Jun 2014 | opiate dependence | Vilnius University | Completed | No outcome recorded |
| — | NCT02312739 Comparator | Feb 2014 → Mar 2015 | — | University of New Mexico | Completed | No outcome recorded |
| — | NCT01393288 Comparator | Nov 2013 → Nov 2014 | — | University of California, San Francisco | Withdrawn | No outcome recorded |
| — | NCT01684085 Comparator | Oct 2012 → Sep 2014 | post-traumatic stress disorder | Sheba Medical Center | Unknown | No outcome recorded |
| — | NCT01505569 Background | Oct 2011 → Feb 2024 | Ewing sarcoma, atypical teratoid rhabdoid tumor, germ cell tumor, hepatoblastoma +6 | Masonic Cancer Center, University of Minnesota | Completed | No outcome recorded |
| — | NCT03435692 Background | Jul 2011 → Jul 2014 | — | Seattle Children's Hospital | Terminated | No outcome recorded |
| — | NCT00641797 Comparator | Nov 2006 → Dec 2010 | benign paroxysmal positional vertigo | Lehigh Valley Hospital | Completed | No outcome recorded |
| — | NCT00586430 Comparator | Dec 2005 → Jul 2007 | Alzheimer disease | Mayo Clinic | Completed | No outcome recorded |
| — | NCT00715039 Comparator | Oct 2003 → May 2004 | anxiety disorder | Pfizer | Completed | No outcome recorded |
| — | NCT00523185 Comparator | May 2003 → Nov 2004 | alcohol withdrawal | Stanford University | Completed | No outcome recorded |
| — | NCT00597701 Comparator | Apr 2003 → Feb 2008 | alcohol withdrawal delirium | Essentia Health | Completed | No outcome recorded |
Evidence & citations 17 cited values
Every value below carries the sentence it was read from. 134 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lorazépam | “Standard of Care analgosedation of choice using propofol, fentanyl, dexmedetomidine, morphine, hydromorphone, midazolam, or lorazepam administered according to the...” NCT06429657 ↗127“Intravenous moderate sedation (fentanyl 100 mcg and midazolam 2 mg) versus oral analgesia/anxiolysis (lorazepam 2 mg sublingual, hydrocodone/acetaminophen 5/500 mg, and...” NCT01011634 ↗ “Administer Toludesvenlafaxine (40-80 mg daily) or imported Sertraline (50-200 mg daily), supplemented with Lorazepam (0.4-0.8 mg) or Alprazolam (0.4-0.8 mg) as needed for sleep support.” NCT07552246 ↗ “For the purposes of enrollment and analysis all benzodiazepines used for sedation (mainly midazolam and lorazepam) will be considered equivalent.” NCT00826553 ↗ “3-drug combination product containing 50-mg diphenhydramine, 5-mg delayed-release zolpidem and 0.5-mg delayed-release lorazepam.” NCT03331042 ↗ “Anti-emetics (metoclopramide, prochlorperazine and lorazepam) may be prescribed to be used 'as needed' for breakthrough emesis.” NCT01843868 ↗ “Subjects will receive busulfan seizure prophylaxis with levetiracetam, fosphenytoin, or lorazepam per institutional guidelines.” NCT06859424 ↗ “The effect of intramuscular injection of GABA or lorazepam will be compared with buffered isotonic saline” NCT02928328 ↗ “Sedatives/anxiolytics: alprazolam, diazepam, lorazepam, secobarbital, temazepam, triazolam, zolpidem” NCT02033707 ↗ “Subjects will receive single doses of GSK561679, lorazepam, or placebo at each treatment session.” NCT00513565 ↗ “3-drug combination product containing 50 mg diphenhydramine, 5 mg zolpidem and 0.5 mg lorazepam” NCT04396327 ↗ “3-drug combination product containing 50 mg diphenhydramine, 5 mg zolpidem and 0.5 mg lorazepam” NCT02671760 ↗ “SM-1 is a combination drug product containing diphenhydramine, zolpidem and lorazepam.” NCT03338764 ↗ “Lorazepam is a benzodiazepine that is widely used for management of acute agitation.” PMID 33692709 ↗ Feb 2021 “the following benzodiazepines (bolus + continuous infusion): lorazepam or midazolam” NCT02056236 ↗ “Associations with Lorazepam if necessary will be allowed in any phase of the study.” NCT06467474 ↗ “a single dose of a parenteral benzodiazepine (lorazepam, midazolam, or diazepam)” NCT06549426 ↗ “Lorazépam drug (0,038 mg/kg) on a single oral intake” NCT00696033 ↗ “- Lorazepam 1-10 mg/d. N05BA06” NCT01305707 ↗ “the benzodiazepine lorazepam” NCT01050478 ↗ “Lorazepam OR Levetaracetam” NCT01505569 ↗ “one 1mg Lorazepam tablet” NCT02312739 ↗ |
| Known as | Abbloraz | ChEMBL registry synonym — accepted as the source's own label CHEMBL580 ↗ |
| Known as | Ativan | “Gabapentin (Neurontin) will be compared to a standard benzodiazepine, lorazepam (Ativan), for its effectiveness in treating alcohol withdrawal.” NCT00011297 ↗5“Haldol 5mg/ Ativan 2mg IM” NCT00786318 ↗ “Xanax, Valium, Ativan” NCT03053869 ↗ “lorazepam (Ativan)” NCT00000441 ↗ |
| Known as | Intravenous route of active treatment | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00809146 ↗ |
| Known as | Loraz | ChEMBL registry synonym — accepted as the source's own label CHEMBL580 ↗ |
| Known as | Lorazepam civ | ChEMBL registry synonym — accepted as the source's own label CHEMBL580 ↗ |
| Known as | Lorazepam intensol | ChEMBL registry synonym — accepted as the source's own label CHEMBL580 ↗ |
| Known as | Lorazepam Mylan | “Lorazepam Mylan 2,5 mg tabletten 2.5mg Oral use Single dose 45 minutes before dental treatment” NCT02078336 ↗ |
| Known as | Lorazepam preservative free | ChEMBL registry synonym — accepted as the source's own label CHEMBL580 ↗ |
| Known as | Loreev xr | ChEMBL registry synonym — accepted as the source's own label CHEMBL580 ↗ |
| Known as | LZP | “comparing acute dosing (i.e., two doses) of BRV 10 mg, LEV 500 mg, lorazepam (LZP) 2 mg, and placebo.” PMID 20887370 ↗ Sep 20101“one (1) dose of a comparator drug (lorazepam-LZP)” NCT01889602 ↗ |
| Known as | NSC-289758 | ChEMBL registry synonym — accepted as the source's own label CHEMBL580 ↗ |
| Known as | Temesta | ChEMBL registry synonym — accepted as the source's own label CHEMBL580 ↗ |
| Known as | WY-4036 | ChEMBL registry synonym — accepted as the source's own label CHEMBL580 ↗ |
| Action | Activate | “standard use of GABA agonist sedatives such as lorazepam” NCT00095251 ↗ |
| Modality | Small molecule | “a standard benzodiazepine, lorazepam (Ativan)” NCT00011297 ↗ |
| Route | Intravenous | “Patients receive intravenous diazepam, lorazepam, or placebo during transport.” NCT00004297 ↗ |